Clarinex-D 12 Hour

Clarinex-D 12 Hour is a brand name of desloratadine/pseudoephedrine, approved by the FDA in the following formulation(s):

CLARINEX-D 12 HOUR (desloratadine; pseudoephedrine sulfate - tablet, extended release; oral)

• 
  Manufacturer: SCHERING
  
  Approval date: February 1, 2006
  
  Strength(s): 2.5MG;120MG ^[RLD]

Has a generic version of Clarinex-D 12 Hour been approved?

No. There is currently no therapeutically equivalent version of Clarinex-D 12 Hour available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Clarinex-D 12 Hour. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  8-chloro-6,11-dihydro-11- ] (4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
  Patent 6,100,274
  Issued: August 8, 2000
  Inventor(s): Kou; Jim H.
  Assignee(s): Schering Corporation
  Stable pharmaceutical compositions containing 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cycloheptic[1,2-b ]pyridine("DCL") and a DCL protective amount of a pharmaceutically acceptable basic salt such as calcium dibasic phosphate and an amount of at least one disintegrant, preferably two disintegrates such as microcrystalline cellulose and starch sufficient to provide dissolution of at least about 80% by weight of the pharmaceutical composition in about 45 minutes and suitable for oral administration to treat allergic reactions in mammals such as man are disclosed.
  
  Patent expiration dates:
  
  
  • July 7, 2019
    
    ✓ 
    Drug product
  
  
  
  • January 7, 2020
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Extended release oral dosage composition
  Patent 6,709,676
  Issued: March 23, 2004
  Inventor(s): Wing-Kee Philip; Cho
  Assignee(s): Schering Corporation
  A bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b) a sustained release second layer comprising an effective amount of a nasal decongestant, e.g. pseudoephedrine sulfate and a pharmaceutically acceptable sustained release agent wherein the composition contains less than about 2% of desloratadine decomposition products is disclosed. A solid composition comprising an anti-allergic effective amount of desloratadine and at least one, and preferably two pharmaceutically acceptable antioxidants is also disclosed.
  
  Patent expiration dates:
  
  
  • February 18, 2021
    
    ✓ 
    Patent use: ALLERGIC RHINITIS
    ✓ 
    Drug product
  
  



• 
  Compositions of descarboethoxyloratadine
  Patent 7,214,683
  Issued: May 8, 2007
  Inventor(s): Aberg; A. K. Gunnar & McCullough; John R. & Smith; Emil R.
  Assignee(s): Sepracor Inc.
  Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
  
  Patent expiration dates:
  
  
  • December 30, 2014
    
    ✓ 
    Drug product
  
  
  
  • June 30, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Methods for the treatment of allergic rhinitis
  Patent 7,214,684
  Issued: May 8, 2007
  Inventor(s): Aberg; A. K. Gunnar & McCullough; John R. & Smith; Emil R.
  Assignee(s): Sepracor Inc.
  Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
  
  Patent expiration dates:
  
  
  • December 30, 2014
    
    ✓ 
    Patent use: TREATMENT OF ALLERGIC RHINITIS
  
  
  
  • June 30, 2015
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Extended release oral dosage composition
  Patent 7,618,649
  Issued: November 17, 2009
  Inventor(s): Cho; Wing-Kee Philip
  Assignee(s): Schering Corporation
  A bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b) a sustained release second layer comprising an effective amount of a nasal decongestant, e.g. pseudoephedrine sulfate and a pharmaceutically acceptable sustained release agent wherein the composition contains less than about 2% of desloratadine decomposition products is disclosed. A solid composition comprising an anti-allergic effective amount of desloratadine and at least one, and preferably two pharmaceutically acceptable antioxidants is also disclosed.
  
  Patent expiration dates:
  
  
  • December 19, 2020
    
    ✓ 
    Patent use: A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
    ✓ 
    Drug product
  
  
  
  • June 19, 2021
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Clarinex-D 12 Hour Consumer Information (Drugs.com)
• Clarinex-D 12 Hour Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• Clarinex-D 12 Hour Consumer Information (Cerner Multum)
• Desloratadine/Pseudoephedrine Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• Desloratadine and pseudoephedrine Consumer Information (Cerner Multum)
• Clarinex-D Advanced Consumer Information (Micromedex)
• Desloratadine and pseudoephedrine Advanced Consumer Information (Micromedex)